Target intelligence / Profile preview

Proteasome activator complex subunit gamma (PA28γ)

Target
PA28γ
Molecular classification
Enzyme regulator, Proteasome regulatory subunit, Proteasome activator
01

Overview

Proteasome activator complex subunit gamma (PA28γ, encoded by the PSME3 gene) is a regulatory component of the 11S proteasome activator complex. Unlike its α and β paralogs (which function predominantly in the immunoproteasome), PA28γ forms a nuclear-localized homoheptameric complex that binds to the 20S proteasome core, enhancing the degradation of several regulatory nuclear proteins in an ATP- and ubiquitin-independent manner. This activity is implicated in pivotal cellular processes including cell cycle progression, apoptosis, chromatin remodeling, and the DNA damage response. PA28γ also interacts with proteins such as p53 and Mdm2, contributing to the regulation of tumor suppression pathways. Dysregulation or overexpression of PA28γ has been associated with cancer and viral infections, but there are no approved drugs specifically targeting this subunit, and inhibiting it may have significant cellular consequences due to its fundamental role in proteostasis.

Other names
PA28 gammaREG gamma11S regulator gamma subunitProteasome activator subunit 3PSME3
02

Mechanism of action

Enhancement of 20S proteasome-mediated protein degradation (notably of regulatory proteins); Modulation of apoptosis and cell cycle through protein turnover; Regulation of immune function via non-classical pathways (distinct from PA28α/β, which are more involved in MHC class I antigen presentation)

03

Biological functions

Protein degradation (ATP-independent)Cell cycle regulationApoptosisCell proliferationRegulation of chromatin structure and organizationDNA damage response
04

Disease associations

Cancer (implicated in cell proliferation/apoptosis and p53 regulation)Potential roles in neurodegeneration and viral infection (e.g., stabilization of hepatitis B virus X protein)
05

Safety considerations

As a general protein turnover regulator, manipulation may cause broad effects on cell viability, proliferation, and apoptosisPotential to disrupt essential nuclear protein degradation, leading to unforeseen off-target effects
06

Biomarkers

No established clinical biomarkers; altered expression is observed in some cancers and in response to cellular stress, so potential use in research as a proliferation/apoptosis biomarker

Beyond the preview

Go deeper on Proteasome activator complex subunit gamma (PA28γ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome activator complex subunit gamma (PA28γ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call